CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
CEO Jorge Santos da Silva reported the sale of 150,000 shares of the MoonLake Immunotherapeutics (NASDAQ:MLTX) through multiple open market operations on April 10, 2026 and April 13, 2026, according to SEC Form 4 filings.
|
Metric |
Price |
|---|---|
|
Shares sold (direct) |
150,000 |
|
Transaction amount |
~$2.8 million |
|
Post-trade shares (direct) |
2,924,893 |
|
Post-transaction value (direct ownership) |
~$53.9 million |
Transaction price based on SEC Form 4 weighted average purchase price ($18.35); post transaction value based on market closing price on April 13, 2026.
-
How does the size of this transaction compare to Mr. Santos da Silva?
This sale of 150,000 shares is more than his estimated sale size of approximately 107,000 shares, and is his second largest sale on the open market since October 2023. -
What is the proportion of shares of Mr. Santos da Silva affected?
The transaction reduced his direct ownership by 4.9%, leaving him with 2,924,893 shares of Common Stock. -
Does the transaction involve any indirect companies or derivative securities?
No, all shares are sold directly by Mr. Santos da Silva; there were no transactions involving family trusts, LLCs, or options in this filing. -
What does this exercise mean about the remaining potential for additional share sales?
With 2,924,893 shares outstanding directly and additional Class A common shares, Mr. Santos da Silva maintains a high volume of sales, and the trade is in line with the cadence established in the last eighteen months.
|
Metric |
Price |
|---|---|
|
Price (as of market close on 4/13/26) |
$18.43 |
|
Market capitalization |
$1.35 billion |
|
Total revenue (TTM) |
$227.32 million |
|
1 year price change |
-47.47% |
* 1-year performance calculated using April 13, 2026 as reference date.
-
MoonLake Immunotherapeutics is developing Sonelokimab, a novel Nanobody therapy, currently in Phase II trials for inflammatory diseases such as hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis.
-
The company operates as a clinical-stage biopharmaceutical business, generating value through research, clinical development, and potential future commercialization or licensing of new immunotherapeutic assets.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company headquartered in Zug, Switzerland, with approximately 100 employees.
The company uses proprietary Nanobody technology to address important unmet needs in the inflammatory disease market. Its strategic focus on advanced clinical programs and novel therapeutic platforms positions it to compete in the evolving immunology landscape.
The April 10 and 13 sale of MoonLake Immunotherapeutics stock by CEO Jorge Santos da Silva is not a cause for concern for investors. He retained nearly three million shares after the transaction, indicating that he is in no rush to dispose of his holdings.
That said, shares of MoonLake Immunotherapeutics are down sharply from a 52-week high of 62.75 reached last September. The fall was due to disappointing clinical trial results for its treatment Sonelokimab.
Since then, MoonLake received an expedited designation for Sonelokimab from the US Food and Drug Administration (FDA). This is an encouraging sign that suggests the treatment could reach the market sooner, but that depends on how well it works in ongoing clinical trials. Its latest findings since the end of March have provided encouraging results.
For investors, MoonLake Immunotherapeutics remains a risky stock. Until the company receives FDA approval for Sonelokimab, MoonLake is not generating revenue. Its operating expenses are estimated at $65 million per quarter, and it has $394 million in cash on its balance sheet at the end of 2025. It has funds to support operations for a while, but investing in a company requires investors to have a high risk tolerance.
Before buying stock in MoonLake Immunotherapeutics, consider the following:
I The Motley Fool Stock Advisor a team of analysts has just identified what they believe to be 10 best stocks for investors to buy now… and MoonLake Immunotherapeutics was not one of them. The 10 stocks that made the cut could produce huge gains in the coming years.
Think about when Netflix made this list on December 17, 2004… if you invested $1,000 during our recommendation, you will have $524,786!* Whenever Nvidia made this list on April 15, 2005… if you invested $1,000 during our recommendation, you will have $1,236,406!*
Now, it’s worth noting Stock Advisor’s the average total return is 994% – outperformed the market compared to 199% of the S&P 500. Don’t miss the latest top 10 list, available via Stock Advisorand join an investment community built by individual investors for individual investors.
See 10 stocks »
*The Stock Advisor returns as of April 18, 2026.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a policy of disclosure.
CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? was first published by The Motley Fool
